← All trials
NCT05986084
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2023
- Primary completion
- Oct 31, 2027
- Completion date
- Jun 30, 2028
- First posted
- Aug 14, 2023
- Last posted
- Aug 14, 2023
- Enrollment
- 500
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- ViiV HealthcareCollaborator
- National Institutes of Health (NIH)Collaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Botswana Harvard Aids InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.